EUVIMEDEUVIMED entdecken
Crossref

RANK and RANKL Expression in Tumors of Patients with Early Breast Cancer

Annika Behrens, Lena Wurmthaler, Felix Heindl, Paul Gass, Lothar Häberle, Bernhard Volz, Carolin C. Hack, Julius Emons, Ramona Erber, Arndt Hartmann, Matthias W. Beckmann, Matthias Ruebner und 4 weitere

TumorDiagnostik & Therapie · 01.03.2024 · 45 (02) · 112-119

DOI: 10.1055/a-2257-9565 ↗

Kurz gefasst

Fachartikel in der Zeitschrift TumorDiagnostik & Therapie, erschienen am 01.03.2024. Verfasst von Annika Behrens und 15 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben. Gefördert von: Bavaria California Technology Center, California Breast Cancer Research Program, Dr. Mildred Scheel Foundation of German Cancer Aid.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The receptor activator of nuclear factor-κB (RANK) pathway was associated with the pathogenesis of breast cancer. Several studies attempted to link the RANK/RANKL pathway to prognosis; however, with inconsistent outcomes. We aimed to further contribute to the knowledge about RANK/RANKL as prognostic factors in breast cancer. Within this study, protein expression of RANK and its ligand, RANKL, in the tumor tissue was analyzed in association with disease-free survival (DFS) and overall survival (OS) in a study cohort of patients with early breast cancer. 607 samples of female primary and early breast cancer patients from the Bavarian Breast Cancer Cases and Controls Study were analyzed to correlate the RANK and RANKL expression with DFS and OS. Therefore, expression was quantified using immunohistochemical staining of a tissue microarray. H-scores were determined with the cut-off value of 8.5 for RANK and 0 for RANKL expression, respectively. RANK and RANKL immunohistochemistry were assessed by H-score. Both biomarkers did not correlate (ρ = −0.04). According to molecular subtypes, triple-negative tumors and HER2-positive tumors showed a higher number of RANK-positive tumors (H-score ≥ 8.5), however, no subtype-specific expression of RANKL could be detected. Higher RANKL expression tended to correlate with a better prognosis. However, RANK and RANKL expression could not be identified as statistically significant prognostic factors within the study cohort. Tumor-specific RANK and RANKL expressions are not applicable as prognostic factors for DFS and OS, but might be associated with subtype-specific breast cancer progression.

Förderung

  • Bavaria California Technology Center
  • California Breast Cancer Research Program
  • Dr. Mildred Scheel Foundation of German Cancer Aid

Zitieren

APA

Behrens, A., Wurmthaler, L., Heindl, F., Gass, P., Häberle, L., Volz, B., Hack, C. C., Emons, J., Erber, R., Hartmann, A., Beckmann, M. W., Ruebner, M., Dougall, W. C., Fasching, P. A., Huebner, H., & Press, M. F. (2024). RANK and RANKL Expression in Tumors of Patients with Early Breast Cancer. TumorDiagnostik & Therapie, 45(02), 112-119. https://doi.org/10.1055/a-2257-9565

Vancouver

Behrens A, Wurmthaler L, Heindl F, Gass P, Häberle L, Volz B, et al. RANK and RANKL Expression in Tumors of Patients with Early Breast Cancer. TumorDiagnostik & Therapie. 2024;45(02):112-119. doi:10.1055/a-2257-9565

BibTeX
@article{Behrens2024,
  author = {Behrens, Annika and Wurmthaler, Lena and Heindl, Felix and Gass, Paul and Häberle, Lothar and Volz, Bernhard and Hack, Carolin C. and Emons, Julius and Erber, Ramona and Hartmann, Arndt and Beckmann, Matthias W. and Ruebner, Matthias and Dougall, William C. and Fasching, Peter A. and Huebner, Hanna and Press, Michael F.},
  title = {RANK and RANKL Expression in Tumors of Patients with Early Breast Cancer},
  journal = {TumorDiagnostik & Therapie},
  year = {2024},
  volume = {45},
  number = {02},
  pages = {112--119},
  doi = {10.1055/a-2257-9565}
}
Kostenlos starten →